International Registry for Severe Chronic Neutropenia

Status Recruiting

Clinical Trial Summary

OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN). II. Monitor and assess long term safety of primary treatment in SCN patients in the United States, Canada, Europe, and Australia. III. Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly, cytogenetic abnormalities, myelodysplastic syndrome, and leukemia. IV. Evaluate growth and development and hematologic parameters. V. Monitor for clinically significant changes in primary treatment response over time. VI. Establish a physician network to increase the understanding of SCN. VII. Establish a demographic database to allow for future research.

Clinical Trial Description

PROTOCOL OUTLINE: Patients are treated by the referring physician as medically indicated. Clinical data are collected at baseline and then every 6 months. ;

Study Design

Related Conditions & MeSH terms

Neutropenia

Clinical Trial Details

NCT number	NCT00004342
Study type	Observational
Source	National Center for Research Resources (NCRR)
Contact
Status	Recruiting
Phase
Start date	June 1994

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02452034` - Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)	Phase 1
Not yet recruiting	`NCT02806557` - Profiling Neutrophil Counts in Patients on Chemotherapy	N/A
Not yet recruiting	`NCT01714557` - Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT01371656` - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Phase 3
Active, not recruiting	`NCT00020865` - Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Phase 3
Completed	`NCT00257790` - The Tobramycin Study	Phase 4
Completed	`NCT00020371` - BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy	Phase 1
Terminated	`NCT00005787` - Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00001533` - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine	Phase 1
Completed	`NCT05585463` - Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
Not yet recruiting	`NCT02238873` - Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma	Phase 3
Completed	`NCT01058993` - AMD 3100 for Treatment of Myelokathexis	Phase 1
Completed	`NCT00771810` - Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer	Phase 2
Completed	`NCT00770172` - G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy	Phase 3
Completed	`NCT00771433` - G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer	Phase 2
Terminated	`NCT00529282` - A Study of Ceftobiprole in Patients With Fever and Neutropenia.	Phase 3
Active, not recruiting	`NCT00030758` - Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer	Phase 4
Completed	`NCT00001790` - Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia	Phase 1
Completed	`NCT00002693` - Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia	Phase 1
Active, not recruiting	`NCT04154488` - A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders	Phase 1/Phase 2